Dr Danielle Bond
Post-Doctoral Research Scientist
School of Biomedical Sciences and Pharmacy
- Email:danielle.bond@newcastle.edu.au
- Phone:40420872
Career Summary
Biography
Dr Danielle Bond is an Early Career Researcher with the University of Newcastle’s School of Biomedical Sciences and Pharmacy. She is based at the Hunter Medical Research Institute (HMRI) and is associated with the Hunter Cancer Research Alliance (HCRA). Dr Bond’s research is focused on exploring the epigenetic changes that occur in cancer patients following drug treatment. This includes conducting groundwork research into the emerging role of tumour microenvironments on prognosis, treatment response and resistance.
Dr Bond completed her PhD in medical biochemistry with the University of Newcastle in 2015. Her studies explored the post-transcriptional regulation of CD9 and CD151 by micro-RNAs in breast and prostate cancers. From 2015 to 2017, Dr Bond tested novel, natural and synthetic compounds, such as Vietnamese medicinal plants, as anti-pancreatic cancer agents. She was also involved in investigating blood markers for prostate cancer at the Ourimbah campus of the University of Newcastle.
In 2018, Dr Bond joined the Cancer Epigenetics group, led by Dr Heather Lee, as a postdoctoral scientist. Her role involved using cutting-edge single cell sequencing technology to test epigenetic processes such as DNA methylation and gene expression in Leukemia patients following treatment with cancer therapies. Dr Bond also undertook research to identify novel markers that could predict patient prognosis and response to current cancer treatments.
Dr Bond has presented her research at both national and international conferences and continues to publish her findings in high-impact journals. She has helped organise local scientific meetings and served as an RHD representative for the school research committee and deputy convenor of the Australian Society for Medical Research (ASMR) Newcastle committee.
Dr Bond has received pilot grant funding through the Faculty of Health and Medicine at the University of Newcastle and project funding from a CFMEU donor grant from HMRI. She is currently striving towards building an independent research program that aims to investigate epigenetic and transcriptional heterogeneity in cancer cells and their surrounding microenvironment in response to cancer therapy, with the help of a HMRI Leukemia Donor Grant received in late 2018.
Qualifications
- Doctor of Philosophy, University of Newcastle
- Bachelor of Biomedical Sciences, University of Newcastle
- Bachelor of Biomedical Sciences (Hons), University of Newcastle
Keywords
- Acute Myeloid Leukemia
- Breast Cancer
- DNA Methylation
- Drug Discovery
- Epigenetics
- Gene Expression
- Myelodsyplastic Syndrome
- Pancreatic Cancer
- Prostate Cancer
- Tetraspanins
- micro-RNA
Languages
- English (Mother)
Fields of Research
| Code | Description | Percentage |
|---|---|---|
| 111201 | Cancer Cell Biology | 80 |
| 111204 | Cancer Therapy (excl. Chemotherapy and Radiation Therapy) | 20 |
Professional Experience
UON Appointment
| Title | Organisation / Department |
|---|---|
| Casual Lecturer | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
| Post-Doctoral Research Scientist | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
Academic appointment
| Dates | Title | Organisation / Department |
|---|---|---|
| 6/04/2015 - 31/12/2016 | Research Associate | Faculty of Science and Information Technology, The University of Newcastle | Australia Environmental and Life Sciences Australia |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (13 outputs)
| Year | Citation | Altmetrics | Link | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 |
Predebon MJ, Bond DR, Brzozowski J, Jankowski H, Deane F, Tarleton M, et al., 'The bispidinone derivative 3,7-Bis-[2-(S)-amino-3-(1H-indol-3-yl)-propionyl]-1,5-diphenyl-3,7-diazabicyclo[3.3.1]nonan-9-one dihydrochloride induces an apoptosis-mediated cytotoxic effect on pancreatic cancer cells in vitro', Molecules, 24 (2019) [C1]
|
||||||||||
| 2018 |
Brzozowski JS, Jankowski H, Bond DR, McCague SB, Munro BR, Predebon MJ, et al., 'Lipidomic profiling of extracellular vesicles derived from prostate and prostate cancer cell lines.', Lipids Health Dis, 17 211 (2018) [C1]
|
||||||||||
| 2018 |
Brzozowski JS, Bond DR, Jankowski H, Goldie BJ, Burchell R, Naudin C, et al., 'Extracellular vesicles with altered tetraspanin CD9 and CD151 levels confer increased prostate cell motility and invasion', Scientific Reports, 8 1-13 (2018) [C1]
|
||||||||||
| 2018 |
Bond DR, Naudin C, Carroll AP, Goldie BJ, Brzozowski JS, Jankowski HM, et al., 'miR-518f-5p decreases tetraspanin CD9 protein levels and differentially affects non-tumourigenic prostate and prostate cancer cell migration and adhesion', ONCOTARGET, 9 1980-1991 (2018) [C1]
|
||||||||||
| 2018 |
Goldsmith CD, Bond D, Jankowski H, Weidenhofer JC, Stathopoulos C, Roach PD, Scarlett CJ, 'The Olive Biophenols Oleuropein and Hydroxytyrosol Selectively Reduce Proliferation, Influence the Cell Cycle, and Induce Apoptosis in Pancreatic Cancer Cells', International Journal of Molecular Sciences, 19 (2018) [C1]
|
||||||||||
| 2018 |
Hong NTP, Sakoff JA, Bond DR, Quan VV, Bowyer MC, Scarlett CJ, 'In vitro antibacterial and anticancer properties of Helicteres hirsuta Lour. leaf and stem extracts and their fractions', MOLECULAR BIOLOGY REPORTS, 45 2125-2133 (2018) [C1]
|
||||||||||
| 2018 |
Bhuyan DJ, Vuong QV, Bond DR, Chalmers AC, Bowyer MC, Scarlett CJ, 'Eucalyptus microcorys leaf extract derived HPLC-fraction reduces the viability of MIA PaCa-2 cells by inducing apoptosis and arresting cell cycle', Biomedicine and Pharmacotherapy, 105 449-460 (2018) [C1]
|
||||||||||
| 2017 |
Bhuyan DJ, Sakoff J, Bond DR, Predebon M, Vuong QV, Chalmers AC, et al., 'In vitro anticancer properties of selected Eucalyptus species', IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 53 604-615 (2017) [C1]
|
||||||||||
| 2017 |
Bhuyan DJ, Vuong QV, Bond DR, Chalmers AC, van Altena IA, Bowyer MC, Scarlett CJ, 'Exploring the Least Studied Australian Eucalypt Genera: Corymbia and Angophora for Phytochemicals with Anticancer Activity against Pancreatic Malignancies', CHEMISTRY & BIODIVERSITY, 14 (2017) [C1]
|
||||||||||
| 2017 |
Naudin C, Smith B, Bond DR, Dun MD, Scott RJ, Ashman LK, et al., 'Characterization of the early molecular changes in the glomeruli of Cd151 -/- mice highlights induction of mindin and MMP-10.', Scientific Reports, 7 15987-15987 (2017) [C1]
|
||||||||||
| 2016 |
Weidenhofer JC, Colvin EK, Bond DR, Scarlett CJ, 'Animal models of pancreatic cancer and their application in clinical research', Gastrointestinal Cancer : Targets and Therapy, 2016 31-39 (2016) [C1]
|
||||||||||
| 2014 |
Pundavela J, Demont Y, Jobling P, Lincz LF, Roselli S, Thorne RF, et al., 'ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer', American Journal of Pathology, 184 3156-3162 (2014) [C1] © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. Nerve infiltration is essential to prostate cancer progression, but the mechan... [more] © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. Nerve infiltration is essential to prostate cancer progression, but the mechanism by which nerves are attracted to prostate tumors remains unknown. We report that the precursor of nerve growth factor (proNGF) is overexpressed in prostate cancer and involved in the ability of prostate cancer cells to induce axonogenesis. A series of 120 prostate cancer and benign prostate hyperplasia (BPH) samples were analyzed by IHC for proNGF. ProNGF was mainly localized in the cytoplasm of epithelial cells, with marked expression in cancer compared with BPH. Importantly, the proNGF level positively correlated with the Gleason score (n = 104, t<inf>B</inf> = 0.51). A higher level of proNGF was observed in tumors with a Gleason score of =8 compared with a Gleason score of 7 and 6 (P < 0.001). In vitro, proNGF was detected in LNCaP, DU145, and PC-3 prostate cancer cells and BPH-1 cells but not in RWPE-1 immortalized nontumorigenic prostate epithelial cells or primary normal prostate epithelial cells. Co-culture of PC12 neuronal-like cells or 50B11 neurons with PC-3 cells resulted in neurite outgrowth in neuronal cells that was inhibited by blocking antibodies against proNGF, indicating that prostate cancer cells can induce axonogenesis via secretion of proNGF. These data reveal that ProNGF is a biomarker associated with high-risk prostate cancers and a potential driver of infiltration by nerves.
|
||||||||||
| 2014 |
Bond DB, Brzozowski J, Skelding KA, Roselli SR, Weidenhofer J, 'Use of tetraspanins CD151 and CD9 as biomarkers for breast cancer', Breast Cancer Management, 3 123-126 (2014) [C3]
|
||||||||||
| Show 10 more journal articles | |||||||||||
Conference (17 outputs)
| Year | Citation | Altmetrics | Link | |||||
|---|---|---|---|---|---|---|---|---|
| 2019 |
Jankowski H, Munro B, McCague S, Quick G, Brzozowski J, Bond D, et al., 'Vault RNAs Have a Functional Role in Prostate Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)
|
|||||||
| 2017 |
Bond D, Phuong TT, Do TH, Nguyen MK, Weidenhofer J, Scarlett CJ, 'Vietnamese medicinal plant compounds show potent anti-pancreatic cancer activity in vitro', CANCER RESEARCH, Washington, DC (2017)
|
|||||||
| 2017 |
Goldsmith CD, Jankowski H, Bond D, Weidenhofer J, Stathopoulos C, Roach P, Scarlett C, 'The olive biophenol oleuropein selectively induces apoptosis in pancreatic cancer cells in vitro', CANCER RESEARCH, Washington, DC (2017)
|
|||||||
| 2015 |
Jankowski H, Goldie B, Brzozowski J, Bond D, Scarlett C, Skelding KA, Weidenhofer J, 'Differences in extracellular vesicle nucleic acid content show promise as prostate cancer biomarkers', Boston, MA (2015) [O1]
|
|||||||
| 2015 |
Brzozowski J, Coldie B, Jankowski H, Bond D, Scarlett C, Dun M, et al., 'THE EFFECTS OF ALTERED CD9 AND CD151 EXPRESSION ON PROSTATE EXOSOMES', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
| 2015 |
Jankowski H, Goldie B, Brzozowski J, Bond D, Scarlett C, Skelding K, Weidenhofer J, 'PROSTATE CANCER BIOMARKERS: ARE EXTRACELLULAR VESICLES THE SOLUTION?', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
| 2015 |
Bond D, Turner A, Richmond R, Sadeqzadeh E, Vuong Q, Bhuyan D, et al., 'THE SEARCH FOR NOVEL TREATMENT AGENTS FOR PANCREATIC CANCER: TALES FROM THE LAND AND SEA', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
| 2015 |
Predebon M, Bond D, Brzozowski J, Jankowski H, Deane F, Tarleton M, et al., 'A BISPIDINONE ANALOGUE INDUCES AN APOPTOSIS-MEDIATED CYTOTOXIC EFFECT ON PANCREATIC CANCER CELLS IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
| 2014 |
Bond DR, Passfield C, Cairns M, Ashman LK, Weidenhofer J, 'Posttranscriptional regulation of tetraspanins CD151 & CD9 in breast & prostate cancers', CANCER RESEARCH, San Diego, CA (2014) [E3]
|
|||||||
| 2013 |
Weidenhofer J, Bond D, Copeland B, Ashman L, 'Tetraspanin protein turnover rates vary in prostate cancer cell lines', BJU INTERNATIONAL (2013) [E3]
|
|||||||
| 2013 |
Bond D, Cairns M, Ashman L, Weidenhofer J, 'Post-transcriptional regulation of CD151 & CD9 by miRNAs in prostate cancer', BJU INTERNATIONAL (2013) [E3]
|
|||||||
| 2012 |
Bond DR, Cairns MJ, Ashman LK, Weidenhofer JC, 'Investigating micro-RNA regulation of tetraspanins CD151 and CD9 in prostate cancer', Febs Journal, Seville, Spain (2012) [E3]
|
|||||||
| Show 14 more conferences | ||||||||
Grants and Funding
Summary
| Number of grants | 3 |
|---|---|
| Total funding | $425,000 |
Click on a grant title below to expand the full details for that specific grant.
20181 grants / $20,000
Investigating the role of stromal heterogeneity in Myelodysplastic Syndrome following Azacitadine therapy $20,000
Funding body: Hunter Medical Research Institute
| Funding body | Hunter Medical Research Institute |
|---|---|
| Project Team | Doctor Danielle Bond, Doctor Heather Lee, Doctor Anoop Enjeti |
| Scheme | Project Grant |
| Role | Lead |
| Funding Start | 2018 |
| Funding Finish | 2018 |
| GNo | G1801353 |
| Type Of Funding | C3120 - Aust Philanthropy |
| Category | 3120 |
| UON | Y |
20141 grants / $400,000
Tetraspanin CD9; more than just an exosome marker - A novel biomarker to target for prostate cancer$400,000
Funding body: Hunter Medical Research Institute
| Funding body | Hunter Medical Research Institute |
|---|---|
| Project Team | Doctor Jude Weidenhofer, Doctor Kathryn Skelding, Doctor Matt Dun, Ms Belinda Goldie, Doctor Danielle Bond |
| Scheme | Project Grant |
| Role | Investigator |
| Funding Start | 2014 |
| Funding Finish | 2017 |
| GNo | G1400921 |
| Type Of Funding | C3120 - Aust Philanthropy |
| Category | 3120 |
| UON | Y |
20111 grants / $5,000
Investigation of miRNA targeting of tetraspanins CD151 and CD9 in breast cancer $5,000
Funding body: The Faculty of Health, The University of Newcastle
| Funding body | The Faculty of Health, The University of Newcastle |
|---|---|
| Project Team | Judith Weidenhofer, Murray Cairns & Danielle Bond |
| Scheme | Faculty of Health Pilot Grant |
| Role | Investigator |
| Funding Start | 2011 |
| Funding Finish | 2011 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
Research Supervision
Number of supervisions
Current Supervision
| Commenced | Level of Study | Research Title | Program | Supervisor Type |
|---|---|---|---|---|
| 2020 | PhD | Epigenetic Heterogeneity and Dynamics in Acute Myeloid Leukaemia | PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle | Co-Supervisor |
| 2019 | PhD | The Link Between Aberrations in the P53 Pathway and Outcome from DNA-Damaging Therapies in Breast Cancer | PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle | Co-Supervisor |
| 2017 | PhD | Targeting Cancer-Initiating Cells with DNA Methyltransferase Inhibitors: Single-cell Analysis to Decipher Molecular Mechanisms and Improve Efficacy | PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle | Co-Supervisor |
Dr Danielle Bond
Positions
Post-Doctoral Research Scientist
Cancer Epigenetics
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
Casual Lecturer
Cancer Epigenetics
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
Contact Details
| danielle.bond@newcastle.edu.au | |
| Phone | 40420872 |
Office
| Room | Level 3 West |
|---|---|
| Building | HMRI |
| Location | HMRI , |
